New Review on PROSTVAC(TM) published by key Investigators from NCI>
New Review on PROSTVAC(TM) published by key Investigators from NCI
(Thomson Reuters ONE) - New Review on PROSTVAC(TM) published by key Investigators from NCIA just published Review in the publication "Expert Opinion onInvestigational Drugs", Volume 18, Issue 7 2009, confirms theprevious published information on PROSTVAC(TM). This is the mostcomprehensive and updated Review on PROSTVAC(TM) so far.Quote from the article: "Preliminary clinical trials have indicatednegligible toxicity, and Phase II trials have suggested a survivalbenefit after treatment with PROSTVAC(TM), especially in patientswith indolent disease characteristics."Anders Hedegaard, President & CEO of Bavarian Nordic said: "We arevery pleased that the scientific experts once again confirm theirpositive view on PROSTVAC(TM) and the potential use of the vaccine inearlier stages of the disease. We are looking forward to publish moredata at a later stage."Background information:PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinicaldevelopment that has the potential to extend the lives of people withadvanced prostate cancer. Administered subcutaneously, it induces aspecific, targeted immune response that attacks prostate cancercells. Conventional chemotherapy currently used to treat prostatecancer has limited survival rates and is often associated withnumerous side effects. In contrast, PROSTVAC(TM) has the potential toextend survival with improved quality of life. PROSTVAC is beingdeveloped in collaboration with the National Cancer Institute under aCooperative Research and Development Agreement with Bavarian Nordic'sU.S.-based subsidiary, BN ImmunoTherapeutics.In clinical trials to date PROSTVAC(TM) and related PSA containingpoxviral vaccines have been investigated in more than 500 patientsfor 10 years.Asger AamundChairmanhttp://hugin.info/100065/R/1326536/312223.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Océ publishes 2nd quarter 2009 results>
">
" alt="Total voting rights>
">Datum: 01.07.2009 - 08:50 Uhr
Sprache: Deutsch
News-ID 1002274
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New Review on PROSTVAC(TM) published by key Investigators from NCI>
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
